Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy

  • By

  • Conghui Shang

  • Hao Wang

  • Jindong Chen

  • Shuhui Cao

  • Yingjia Sun

  • Ziyi Sheng

  • Tianqing Chu

  • Liang Zhao

  • December 27, 2025

Share

Clinical Scorecard: Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy

At a Glance

CategoryDetail
Condition
Key MechanismsARNIs block RAAS and potentiate natriuretic peptides, potentially mitigating cardiotoxicity from ICIs by reducing inflammation and improving cardiac function.
Target Population
Care Setting

Key Highlights

  • Study investigates ARNIs' effects on lung cancer patients with hypertension receiving ICIs.
  • Primary endpoint: all-cause mortality; secondary endpoint: cardiovascular outcomes.
  • ARNIs may reduce cardiotoxicity from immune checkpoint inhibitors.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular assessment of BNP and cTnI levels every three months post-ICI initiation; consider echocardiograms if abnormalities are detected.

      Risks

        Patient & Prescribing Data

        ARNIs treatment should ideally be initiated prior to ICI therapy to maximize cardiovascular protection.

        Clinical Best Practices

        • Implement propensity score matching to balance treatment groups in observational studies to reduce bias.
        • Utilize Kaplan-Meier method for survival analysis in clinical research to accurately estimate survival probabilities.

        Related Resources & Content

        Original Source(s)

        Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy

        • by Conghui Shang, Hao Wang, Jindong Chen, Shuhui Cao, Yingjia Sun, Ziyi Sheng, Tianqing Chu, Liang Zhao

        • December 27, 2025

        Related Content

        Tricuspid regurgitation thresholds reassessed

        The proposed framework classified 30% of patients as high or extreme risk, compared with 12% classified as having severe or greater tricuspid regurgitation under established grading schemes.

        FDA adds generic valganciclovir oral solution

         The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.

        An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial